Velocity Clinical Research

Velocity Clinical Research Velocity is the world's leading integrated site organization.

Next month, Nick Spittal, COO, will join a panel at the Medidata Solutions NEXT Conference focused on the innovations sh...
02/27/2026

Next month, Nick Spittal, COO, will join a panel at the Medidata Solutions NEXT Conference focused on the innovations shaping the next generation of clinical trials.

The discussion, Site Perspective Panel: Innovation for the Next Generation of Clinical Trials, will explore three key areas poised to streamline trials and reduce burden across stakeholders:
• AI & Intelligent Automation — Simplifying protocols and reducing system overload
• Protocol Optimization & Study Start-Up — Injecting site insights earlier to shorten activation timelines
• Patient-Centricity — Addressing recruitment and retention barriers to improve access

Panelists include:
• Christina Brennan, MD, SVP, Clinical Research, Northwell Health
• Irfan Khan, MD, CEO, Circuit Clinical
• Lisa Moneymaker, SVP & Chief Strategy Officer, Medidata

If you’re attending Medidata NEXT, join the session—and connect with Nick while you’re there.

How can sites diversify therapeutic areas without compromising quality?Next week, Evelyne Newton will share Velocity’s p...
02/26/2026

How can sites diversify therapeutic areas without compromising quality?

Next week, Evelyne Newton will share Velocity’s perspective on strategic therapeutic expansion SCRS Europe.

Through programmes like PIVOT, our experienced P*s train and mentor across the network, accelerating capability building while protecting quality. And when new sites join Velocity, they gain access to shared expertise and infrastructure that supports sustainable growth.

Diversification should strengthen your core not dilute it.

Read more: https://velocityclinical.com/diversifying-therapeutic-areas-from-opportunistic-growth-to-strategic-advantage/

Clinical research is changing—and the industry is demanding greater predictability, transparency, and data integrity tha...
01/30/2026

Clinical research is changing—and the industry is demanding greater predictability, transparency, and data integrity than ever before.

Andrew Reina, Chief Revenue Officer, shares why the traditional, relationship‑driven approaches to site selection are no longer enough—and how AI is reshaping feasibility into a more evidence‑driven, consistent, and confident process.

In his new article, Drew explores:
🔹 Why site selection needs a data reset as Sponsors push for trials that start faster and perform more predictably
🔹 How AI can transform feasibility from opinion-based to evidence-based decision-making
🔹 Why predictability is foundational to data quality—and how better alignment between protocol demands and site capabilities can reduce delays and downstream issues
🔹 How Velocity’s integrated network structure turns scale into intelligence, enabling meaningful performance analysis that many individual sites simply can’t support
🔹 How this new approach raises expectations across the network, driving continuous improvement and operational excellence

Velocity’s AI-powered feasibility and site intelligence tool launches its first phase this February—designed to bring more rigor, clarity, and confidence to site selection decisions.

This is more than a new technology. It’s a step toward a more predictable, data-led clinical research ecosystem—one that strengthens Sponsor relationships with transparent, evidence-backed insights.

Read the full article to see how AI can support your next study with greater confidence and consistency: https://velocityclinical.com/why-site-selection-needs-a-data-reset-and-how-ai-can-deliver-it/

We're gearing up for the SCOPE Summit, taking place February 2–5, 2026 in Orlando, FL. Our leadership team will be on si...
01/26/2026

We're gearing up for the SCOPE Summit, taking place February 2–5, 2026 in Orlando, FL. Our leadership team will be on site to connect, collaborate, and share insights on how Velocity is helping organizations move faster, smarter, and with greater impact.

Attending from Velocity:
• Paul Evans, President & CEO
• Nick Spittal, Chief Operations Officer
• Sarah Smiley, DO, FACP, Chief Physician Officer
• Andrew Reina, Chief Revenue Officer
• Jennifer Kochilaris, SVP, Strategic Partnerships
• Jennifer Carl, VP, Growth & Development
• Paul Kergides, VP, Business Development

If you’re attending SCOPE, we’d love to meet up and discuss the future of clinical research, strategic partnerships, and innovative approaches to operational excellence.

Let’s connect at !

A new article authored by Henrik Watz, MD, Principal Investigator at Velocity’s site in Ahrensburg, Germany, shows that ...
01/26/2026

A new article authored by Henrik Watz, MD, Principal Investigator at Velocity’s site in Ahrensburg, Germany, shows that body mass index (BMI) meaningfully influences COPD symptom scores independent of lung function.

In a large COPD cohort, overweight and obesity were consistently associated with a higher symptom burden and worse quality‑of‑life scores, even after adjustment for lung function, air trapping, gas transfer, exacerbation history, and relevant comorbidities. Symptom scores increased progressively from normal weight to overweight to obesity.

While effect sizes were modest, they were large enough to influence score‑based COPD categorization, suggesting that symptom‑based assessments may partly reflect body weight–related mechanical and systemic effects, not lung disease alone. These findings indicate that BMI should be considered when interpreting COPD symptom scores and risk stratification.

Read the full article: https://pmc.ncbi.nlm.nih.gov/articles/PMC12747889/

At , Nick Spittal will join leaders from Advarra and Immunovant to share insights on how aligned workflows and connecte...
01/23/2026

At , Nick Spittal will join leaders from Advarra and Immunovant to share insights on how aligned workflows and connected technology can reduce inefficiencies and strengthen collaboration among Sponsors, CROs, and research sites.

Make sure to add the session to your calendar:
Meeting Sites Where They Are: Key Connections in Action
Wednesday, February 4, 2026 | 9:50am
Scope 2026 | Rosen Shingle Creek, Orlando

What does it take to lead clinical research with integrity and impact?Dr. Matthew Wenker, Regional Medical Director and ...
01/08/2026

What does it take to lead clinical research with integrity and impact?

Dr. Matthew Wenker, Regional Medical Director and Principal Investigator for Velocity’s Cincinnati sites, shares his journey from hospital medicine to overseeing research across three locations — and nearly 500 studies.

In this interview, Dr. Wenker reflects on the principles that guide his work:
✅ Scientific rigor
✅ Operational consistency
✅ A people-first approach that respects participants and supports colleagues

From early GLP-1 trials to today’s breakthroughs, his perspective on research is as much about human connection as it is about science.

Read the full story here: https://velocityclinical.com/an-interview-with-matthew-wenker-md-on-the-people-first-principles-that-shape-good-clinical-research/

Hello, 2026! 🎉✨As we step into a new year, we’re reflecting on the incredible milestones of 2025—and looking forward to ...
01/01/2026

Hello, 2026! 🎉✨

As we step into a new year, we’re reflecting on the incredible milestones of 2025—and looking forward to even greater impact ahead.

To our patients, thank you for your trust and participation. You are the heart of everything we do.

To our sponsors and partners, thank you for collaborating with us to advance clinical research and bring life-changing therapies to those who need them most.

To our Velocity team worldwide, your dedication and passion make every achievement possible.

Here’s to a year of innovation, collaboration, and improving lives across the globe.

Happy New Year from all of us at Velocity!

Happy Holidays from Velocity! ❄️✨As we wrap up an incredible year, we want to take a moment to express our heartfelt gra...
12/24/2025

Happy Holidays from Velocity! ❄️✨

As we wrap up an incredible year, we want to take a moment to express our heartfelt gratitude to everyone who makes our mission possible:
🎁 To our patients – thank you for your trust and participation. You are the reason we do what we do.
🎁 To our sponsors and partners – thank you for collaborating with us to advance clinical research and bring life-changing therapies to those who need them most.
🎁 To our dedicated staff worldwide – your passion and commitment drive every success we celebrate.

From all of us at Velocity, we wish you a joyful holiday season and a bright, healthy new year. Here’s to continuing our shared journey of innovation and impact in 2026!

🎄 Day 12 of the 12 Days of Velocity: The Greatest Gift—Better Health! ✨We’re wrapping up this year’s celebration with ou...
12/23/2025

🎄 Day 12 of the 12 Days of Velocity: The Greatest Gift—Better Health! ✨

We’re wrapping up this year’s celebration with our most impactful achievement: supporting research that led to 13 FDA product approvals in 2025, bringing our all-time total to 80+ approvals!

These breakthroughs span a wide range of conditions and therapies, including:
🎁 Cardiovascular health – Lerochol for lowering LDL cholesterol
🎁 Rare disease treatment – Sephience for phenylketonuria
🎁 Vaccines – RSV, COVID-19, and Chikungunya (mRESVIA, ABRYSVO, mNEXSPIKE, Nuvaxovid, Vimkunya)
🎁 Dermatology – Anzupgo for chronic hand eczema
🎁 Pediatric care – Enflonsia for RSV prevention in infants
🎁 Migraine relief – Atzumi nasal powder treatment
🎁 Infectious disease – Blujepa for UTIs and Penmenvy meningococcal vaccine

Thanks to our dedicated teams, incredible participants, and valued partners, Velocity is helping bring life-changing therapies to patients faster than ever. Here’s to even greater impact in 2026! ❄️

🎄 Day 11 of the 12 Days of Velocity: Uniting for a Brighter Future! ✨This year, Velocity became a founding member of the...
12/22/2025

🎄 Day 11 of the 12 Days of Velocity: Uniting for a Brighter Future! ✨

This year, Velocity became a founding member of the Association of Multisite Research Corporations (AMRC)—an innovative trade association bringing together 14 leading organizations to tackle systemic challenges in clinical trials.

With 70+ integrated sites across the U.S. and Europe and a network of 1.5M participants, Velocity is proud to champion patient-centric care, superior recruitment, and reliable data collection to accelerate life-saving therapies.
We’re also honored that our President & CEO, Paul Evans, will serve as Vice Chairman of AMRC, helping drive its mission to improve efficiency, inclusivity, and outcomes in clinical research.

Like a holiday tradition of coming together, this collaboration ensures that trials are faster, more accessible, and more impactful for patients everywhere. ❄️

🎄 Day 10 of the 12 Days of Velocity: Leading the Way! ✨This year, Velocity was recognized by AstraZeneca as a top enroll...
12/19/2025

🎄 Day 10 of the 12 Days of Velocity: Leading the Way! ✨

This year, Velocity was recognized by AstraZeneca as a top enrolling site network for Q1 2025, achieving the highest number of randomizations across their biopharma portfolio.

This honor reflects the dedication of our teams worldwide, who work tirelessly to ensure participants are supported, engaged, and enrolled with care and efficiency.
We’re proud to partner with AstraZeneca in advancing innovative therapies—and even more proud to help deliver those treatments to the patients who need them most. ❄️

Address

300 E. Main Street , Suite 300
Durham, NC
27701

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+19199261804

Website

Alerts

Be the first to know and let us send you an email when Velocity Clinical Research posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category